Acute Ischemic Stroke with tpa



Similar documents
PHYSICIAN SIGNATURE DATE TIME DRUG ALLERGIES WT: KG

PHYSICIAN ORDERS TRANSIENT ISCHEMIC ATTACK (TIA) OBSERVATION

Acute Myocardial Infarction (the formulary thrombolytic for AMI at AAMC is TNK, please see the TNK monograph in this manual for information)

Ischemic Stroke Clinical Pathway

Announcements ADMIT order REQUIRED to be entered to complete admission process for all appropriate ordersets.

STATEMENT OF STANDARD

Guidelines and Protocols

A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation

SCRN Medication Review. Susan M. Gaunt MS APRN ACNS-BC CCRN CNRN Gwinnett Medical Center

ACUTE STROKE REGISTRY (NJASR) VERSION 2.0) (Continued)

INR: RUPTURED ANEURYSM: POST EMBOLIZATION Patient Identification Page 1 of 5. Allergies: Weight: kg Diagnosis:

Planning: Patient Goals and Expected Outcomes The patient will: Remain free of unusual bleeding Maintain effective tissue perfusion Implementation

Inpatient Anticoagulation Safety. To provide safe and effective anticoagulation therapy through a collaborative approach.

DVT/PE Management with Rivaroxaban (Xarelto)

Stroke/VTE Quality Measure Build for Meaningful Use Stage 1

Code Stroke: Early Recognition and Emergency Management of the Acute Stroke Patient

Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness SOGH April

REMINDER: Please ensure all stroke and TIA patients admitted to hospital are designated as "Stroke Service" in Cerner.

Prescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients

Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations

Use of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia

ACCIDENT AND EMERGENCY DEPARTMENT/CARDIOLOGY

Update on Antiplatelets and anticoagulants. Outlines. Antiplatelets and Anticoagulants 1/23/2013. Timir Paul, MD, PhD

Suffolk County Community College School of Nursing NUR 133 ADULT NURSING I

Anticoagulation Dosing at UCDMC Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h

Stroke/TIA Interdisciplinary Plan of Care

CHADS score of 5 or 6 Recent (within 3mo) stroke or TIA Rheumatic valvular heart disease CHADs score of 3 or 4

East Kent Prescribing Group

Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2013

Dabigatran (Pradaxa) Guidelines

Anticoagulation Therapy Update

STROKE PREVENTION IN ATRIAL FIBRILLATION

Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence

Venous thromboembolism: reducing the risk. Quick reference guide. Issue date: January 2010

Trust Guideline for Thromboprophylaxis in Trauma and Orthopaedic Inpatients

Traditional anticoagulants

AHA/ASA Ischemic Stroke Performance Measures

Making the Case for CPG s Jean Luciano, MSN, RN, CNRN, SCRN, CRNP, FAHA Claranne Mathiesen, MSN, RN, CNRN, SCRN, FAHA

Appendix L: HQO Year 1 Implementation Priorities

Level III Stroke Center Data Collection Requirements

New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013

LAMC Reversal Agent Guideline for Anticoagulants Time to resolution of hemostasis (hrs) Therapeutic Options

ACUTE STROKE UNIT ORIENTATION

Antiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care

Rx Updates New Guidelines, New Medications What You Need to Know

Overview of the TJC/CMS VTE Core Measures

HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below

Statement of Standard

EMS Management of Stroke. Deaver Shattuck, M.D. Brian Wiseman, M.D. Keith Woodward, M.D.

Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical

Recommendations: Other Supportive Therapy of Severe Sepsis*

Anticoagulants in Atrial Fibrillation

New Anticoagulants: What to Use What to Avoid

Enoxaparin for long term anticoagulation in patients unsuitable for oral anticoagulants

Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto

New Oral Anticoagulants. How safe are they outside the trials?

ABOUT XARELTO CLINICAL STUDIES

Critical Bleeding Reversal Protocol

MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August Anticoagulants

General PROVIDER INITIALS: PHYSICIAN ORDERS

Rivaroxaban (Xarelto ) by

Clinical Pathway Total Hip and Knee Replacement

Session 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy

STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:

Medication Guidelines for LP/Myelograms Medication Recommendation Comments Plavix, Ticlid, other antiplatelet meds

Clinical Guideline N/A. November 2013

convey the clinical quality measure's title, number, owner/developer and contact

The Role of the Newer Anticoagulants

UMHS In-Patient Acute Ischemic Stroke Treatment Guidelines*

Cardiology Medications New Drugs, New Guidelines

ACUTE DVT MANAGEMENT Richard J. DeMasi, MD April 26, 2014

PHYSICIAN SIGNATURE DATE TIME DRUG ALLERGIES WT: KG

New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012

ACCOUNTABLE CARE ORGANIZATION QUICK-REFERENCE SETUP GUIDE

Venous Thromboembolic Treatment Guidelines

Anticoagulant therapy

2.5mg SC daily. INR target mg SC q 12 hr or 40mg daily. 10 mg PO q day (CrCl 30 ml/min). Avoid if < 30 ml/min. 2.

How To Treat An Alcoholic Patient

Optimizing Anticoagulation Selection for Your Patient. C. Andrew Brian MD, FACC NCVH 2015

Chronic Obstructive Pulmonary Disease (COPD) Admission Order Set

A Patient s Guide to Primary and Secondary Prevention of Cardiovascular Disease Using Blood-Thinning (Anticoagulant) Drugs

NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl

Inpatient Quality Reporting Program

Medical Management of Ischemic Stroke: An Update. Siddharth Sehgal, MD Medical Director, TMH Neuroscience Center

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation

What You Need to KnowWhen Taking Anticoagulation Medicine

5/21/2012. Perioperative Use Issues. On admission: During hospitalization:

STROKE PREVENTION AND TREATMENT MARK FISHER, MD PROFESSOR OF NEUROLOGY UC IRVINE

WHY DO MY LEGS HURT? Veins, arteries, and other stuff.

[ ] Cardiac monitoring Routine, Until discontinued, Starting today, PACU (only)

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation

9/5/14. Objectives. Atrial Fibrillation (AF)

CLINICAL QUALITY MEASURES FINALIZED FOR ELIGIBLE HOSPITALS AND CRITICAL ACCESS HOSPITALS BEGINNING WITH FY 2014

Building a Safe Anticoagulation Program By knowing that Safety is not about numbers, Safety is about an attitude..

TSOAC Initiation Checklist

Transcription:

Admission/Condition/Diagnosis Admission: Admitting Physician Attending Physician Assign to Inpatient Status Transfer to Level of Care: Physician MUST document in notes the risk, severity, and skilled nursing need of the patient to justify the status below. ICU Stroke unit Diagnosis: Ischemic Stroke tpa Given Condition: Critical Stable Guarded Consult neurologist (Reminder: Physician to Physician is required) Vital Signs For ICU Patients Vital Signs including abbreviated NIHSS for the first 24 hours. (Q15MIN for 2 hours, then Q30 min for 6 hrs, then QHR for 16 hrs) + Vital Signs & Neuro checks Q1hr and NIHSS Qshift, with neurological changes and at discharge after the first 24 hours For Non ICU Patients Vital Signs including abbreviated NIHSS for the first 24 hours.(q 15min for 2 hours, then Q 30min for 6 hours, then QHR for 16 hours) + Vital Signs & Neuro checks Q4hr and NIHSS Qshift, with neurological changes and at discharge after first 24 hours Core Measure Orders To Include: Mechanical VTE Prophylaxis Core Measure Compliance Orders ( By checking you are ordering the orders listed on page 6) MUST order Intermittent Pneumatic Compression ( IPC) or select or document contraindication No Mechanical Prophylaxis due to: Sequential Compression Device Knee High Amputee Congestive heart failure Patient non-compliant-refused intervention/support. Right AKA Burn to lower limb Mechanical prophylaxis refused (Required) Left AKA Dermatitis o Intermittent pneumatic calf-thigh compression Right BKA Hypervolemia o Venous foot pump Left BKA Deformity of leg Injury to lower extremity Sensory neuropathy Peripheral Vascular Disease Suspected deep vein thrombosis of lower extremity Peripheral ischemia Clouded consciousness Vascular insufficiency of limb Surgical procedure of lower extremity Patient enrolled in clinical trial Edema of leg Lower limb ischemia History of occlusive disease of artery of lower extremity At risk for falls Comfort care management Aspiration Precautions ORDERSET #:ST-BH08 Page 1 or 6 Published: v-4 April 15, 2014 Approved FEBRUARY 2014

Core Measure Medications A. Antiplatelet Do not give antiplatelet for 24 hours post TPA infusion and no hemorrhage on repeat imaging study Aspirin 81 mg 325 mg Oral Daily to start in 24 hours or Aspirin 300 mg Suppository PR daily for NPO pt Dipyridamole Aspirin [Aggrenox] 200mg-25mg SR Cap PO BID to start in 24 hours or Aspirin 300 mg Suppository PR daily for NPO pt Clopidogrel [Plavix] Tab 75mg Oral Daily to start in 24 hours or Aspirin 300 mg Suppository PR daily for NPO pt Medication not needed/indicated (Document reason) B. Anticoagulant: For atrial fibrillation or atrial flutter (current or history of) Do not give anticoagulant for 24 hours post TPA infusion and no hemorrhage on repeat imaging study Warfarin [Coumadin] mg Oral Daily to start tomorrow at 2100 Medication not needed/indicated + Other Anticoagulant/Antithrombotic Medications Enoxaparin [Lovenox] and Heparin are contraindicated if patient prescribed any non-warfarin anticoagulants including the VTE Prophylaxis dose. Dabigatran [Pradaxa] Cap 150mg oral BID to start in 24hrs. Dabigatran [Pradaxa] Cap 75mg oral BID, if CrCl is 15-30ml/min, to start in 24hrs. Rivaroxaban [Xarelto] Cap 20mg oral Daily, to start in 24hrs. Rivaroxaban [Xarelto] Cap 15mg oral Daily, if CrCl is 15-30ml/min, to start in 24hrs. Reasons for not administering antithrombotic/anticoagulant (by end of day 2) Bleeding Hemorrhagic cerebral infarction Anterior cerebral circulation hemorrhagic infarction Posterior cerebral circulation hemorrhagic infarction Renal impairment Medical contraindication Surgical contraindication Platelet count below reference range Blood coagulation disorder due to liver disease Blood coagulation disorder Warfarin therapy started Refusal of treatment by patient Additional reasons for Patient not receiving therapy: Pateint enrolled in clinical trials comfort measures only Patient admitted for elective carotid intervention procedure Page 2 of 6

C. VTE Prophylaxis (Physician should reassess daily) If GFR < 30 ml/min, reduce Enoxaparin dose to 30 mg subq daily Do not give anticoagulant for 24 hours post TPA infusion and no hemorrhage on repeat imaging study Enoxaparin [Lovenox] 40 mg 30mg subq daily to start in 24 hours Exclusion Criteria for VTE Prophylaxis (Check all that apply) Anticoagulation allergy Blood coagulation disorder due to liver disease Acute spinal cord injury Heparin induced thrombocytopenia Platelet count below reference range Indwelling epidural catheter Blood coagulation disorder Renal impairment Lumbar puncture, spinal anesthesia, Hemorrhagic cerebral infarction Refusal of treatment by patient or epidural removed within the last 2 hours Bleeding Patient enrolled in clinical trial Uncontrolled or severe hypertension Anticoagulation not tolerated Comfort care management Hypersensitivity to anticoagulants D. Statin or Other Cholesterol Reducing Medications For LDL greater than or equal to 100 and/or pt on lipid lowering agent prior to admission Simvastatin [Zocor] Tab 20mg oral nightly 40mg oral nightly Other Cholesterol Reducing Medications Atorvastatin [Lipitor] Tab 20mg oral nightly 40mg oral nightly 80mg oral nightly Rosuvastatin [Crestor] Tab 40mg oral nightly Niacin Timed- Release Cap + Simvastatin [Zocor] Niacin Timed Release Cap 500mg oral nightly 750mg oral nightly 1000mg oral nightly + Simvastatin [Zocor] 10mg oral nightly 20mg oral nightly Ezetimibe [Zetia] + Simvastatin [Zocor] Ezetimibe [Zetia] 10mg oral nightly + Simvastatin [Zocor] 10mg oral nightly 20mg oral nightly Page 3 of 6

Medications Blood Pressure Medications (Select one only) Initiate if SBP greater than 180 mmhg or DBP greater than 105 mmhg on 2 readings 10 minutes apart. Target SBP 160-180 mmhg, DBP 90-105 mmhg during and 24HR post TPA. Labetalol [Normodyne] 10MG 20MG 40MG IV PRN. May repeat Q10MIN to max of 300 mg. DO NOT give if pulse less than 60 BPM. Give over 1 min. Labetalol [Normodyne] Infusion -Labetalol [Normodyne] Injection 10MG 20MG 40MG IV bolus. Give over 1 min. DO NOT give if pulse less than 60 BPM. -Labetalol [Normodyne] Infusion 2MG/MIN 4MG/MIN 8MG/MIN IV (Dose range 2 8 mg/min) DO NOT give if pulse less 60 BPM. nicardipine [ Cardene ] Infusion Start IV infusion at 5mg/hour. Titrate by 2.5mg/hour Q5MIN up to 15mg/hour to target BP, then decrease to 3mg/hour. Stroke Work-Up Studies Hemoglobin A1C, Routine Once Trans-thoracic Echo order with doppler, colorflow and bubble study Interpreting Cardiologist Ultrasound Carotid Duplex, bilateral CT head Without contrast With contrast MRI head Without contrast With contrast MRA Brain Without contrast With contrast IV Fluids Start Saline Lock + Maintain Saline Lock + Saline Flush Sodium Chloride 0.9% [Normal Saline] 50ml/hr 75 ml/hr 100ml/hr 125ml/hr Other ml/hr Sodium Chloride 0.45% [1/2 Normal Saline] 50ml/hr 75 ml/hr 100ml/hr 125ml/hr Other ml/hr Page 4 of 6

Consults Diabetic Education Consult For Intracranial Hemorrhage after Alteplase Infusion Administer Cryoprecipitate 5 units/pack Single unit + Type + Screen + Transfuse Cryoprecipitate + Verify patient has signed informed consent for blood and blood products Administer Platelet Pheresis 1 unit + Type + Screen + Transfuse Platelet Pheresis + Verify patient has signed informed consent for blood and blood products Administer aminocaproic acid [Amicar] 5g/250ml NS IV over 1 hour followed by 5g/250ml NS IV at 50ml/hr x 5 hours or until bleeding ceases Page 5 of 6

Core Measure Compliance orders for AIS with TPA Medication communication: Do not give Antithrombotic, Antiplatelet, Anticoagulants or NSAIDs for 24 hours post-tpa infusion & no hemorrhage on repeat imaging study. Refer to the Antiplatelet and Anti-coagulant medication list on the utilities menu under patient education. Notify physician if patient exhibits any of the following during or within 24 hours after Alteplase administration: acute neurological deterioration, new headache, acute hypertension, nausea and vomiting and a 4 point or more increase in the previous NIHSS score: a. Suspect intracranial hemorrhage b. If Alteplase is infusing Stop immediately c. Notify physician immediately d. STAT lab: PT/Aptt, Platelet Count, fibrinogen, type and screen e. STAT non contrast CT of head. Notify Physician if Temp > 99.4 F, Respiratory rate > 24, Systolic BP < 110 or > 180 mmhg, Diastolic BP < 60 or > 105 mmhg, Pulse < 50 or > 110, Blood Glucose > 140 Nursing: Order a non contrast CT of head 24 hrs post TPA. Bedrest Seizure/fall risk precautions Elevate HOB > 30 degrees Document fall risk assessment NPO until after tpa infused then continue NPO until patient passes dysphagia screen or formal swallow study. If pt fails, order nutrition consult. Notify physician if patient passes dysphagia screen for diet order Maintain O2 Sat > 92%. If < 92%, start O2 at 2 liters/min via nasal cannula and notify MD Smoking cessation order : Give pt advice/counseling Dietary consult: For caloric and dietary orders Document that the "Stroke Information & Education for You" booklet and each component of its content was discussed with patient / family / caregiver CBC with auto diff in AM Fasting Lipid panel in AM Comprehensive metabolic panel in AM RN case mgmt / Social Svc consult: To assess/assist with patient needs and initiate discharge planning Pastoral care consult: For patient spiritual assessment as needed Physical therapy consult : evaluate and treat Occupational therapy consult : evaluate and treat Speech therapy order to evaluate and treat and Bedside swallow evaluation (on weekends, call facility operator to connect you to speech voicemail and leave message) PHYSICIAN S PRINTED NAME, SIGNATURE and ID# DATE: TIME: Page 6 of 6